UCLA Study Restores Autism Gene Function in Models
Researchers used CRISPR activation to boost two high-confidence autism risk genes in human neuronal and organoid models.
Updated on Nov. 19, 2026 in Science

UCLA researchers used CRISPR activation to amplify expression of the autism risk genes CHD8 and SCN2A in human stem cell-derived neurons and cerebral forebrain organoids. The approach brought gene activity closer to typical levels and improved several measured features in the mutant models.
Why it matters
The work suggests that enhancer-targeted gene activation could be a therapeutic avenue for autism spectrum disorder, though the findings currently come from laboratory models rather than patients. Because a clinical intervention would need to occur before most pregnancies are typically confirmed, the timeline for any application remains uncertain.
Laboratory measurements in human stem cell-derived models show gene increases only in mutant cells, while healthy cells remained unchanged. Between 15-20% of autism genetic risk comes from de novo mutations, but whether the effects carry over to patients is still unknown.
The players
University of California, Los Angeles (UCLA)
A public research university in Los Angeles whose researchers conducted the CRISPR activation study on autism-linked models.
The details
Researchers targeted gene enhancers rather than promoters to avoid excessive gene expression. CHD8 interventions were administered at 25 days of organoid development, reducing aberrant overgrowth, while SCN2A interventions at 100 days largely restored normal neuronal electrical activity.
Timeline
CHD8 intervention administered at 25 days of organoid development.
SCN2A intervention administered at 100 days of organoid development.
Article on the UCLA CRISPR-A autism research published November 19, 2026.
The Big Picture
The study applies CRISPR activation, a gene-regulation tool, to enhancers rather than promoters to control autism-linked genes. It extends that technique from basic gene-regulation research toward a neurodevelopmental therapeutic hypothesis, though the results are limited to laboratory models.
Any therapy built on this approach would need years of further study before reaching patients. For now, the research offers a laboratory proof of concept rather than a treatment available to families.
The takeaway
Gene-level findings in laboratory models can point to new therapeutic directions, but they must be tested in living systems before they carry meaning for patients. Readers should treat the results as early-stage science.
Further reading
For more on how gene-regulation research is evolving, explore the Life Sciences section.
Source note: This article includes information reported by BioTechniques.






